Balaji Agoram, Ph.D.

Vice President, Clinical Pharmacology
Forty Seven Inc; Arcus Biosciences

“Invaluable contribution from Bing and his Amador team in some critical analysis enabling Ph2 dose selection for multiple compounds – high quality work in double quick time.”

CEO of a NYSE-listed biopharmaceutical company

“Amador provided GLP TK, clinical PK and CSR, population PKPD modeling, SAS exposure-response, and US/EU/Japan submission support, in addition to bioanalytical services in China to us. Amador brings years of industry experience and expertise to the table. Thanks to Amador’s team of clinical pharmacologists, pharmacometricians, SAS programmers and medical writers, we can effectively develop multiple products and conduct global CTD filings with limited internal resources. Highly recommended!"

Rakesh Dixit, Ph.D. DABT

Former VP and Global Head of Biologics
Safety Assessment Pathology and Laboratory Animal Medicine

“The uniqueness of the Amador is its very strong team of biotech professionals with many decades of experience in developing medicines of all classes. No other CRO has this much depth in providing solutions to biotech companies worldwide in developing medicines. The team also has excellent regulatory experience worldwide in filing INDs, NDAs, and BLAs successfully. It is noteworthy that I have worked with most of the US staff of Amador at AstraZeneca for many years and I feel very lucky to work with them again.”